Metabolic syndrome and prostate cancer

Cancer

Volumn 112, Issue 10, 2008, Pages 2103-2105

  Glode, L Michael ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIANDROGEN; BICALUTAMIDE; ESTROGEN DERIVATIVE; GONADORELIN AGONIST; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TRIACYLGLYCEROL;

CANCER RECURRENCE; CARDIOVASCULAR RISK; EDITORIAL; GLUCOSE INTOLERANCE; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; MICROALBUMINURIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO; WORLD HEALTH ORGANIZATION;

ADIPONECTIN; ADIPOSE TISSUE; ANTINEOPLASTIC AGENTS, HORMONAL; BODY MASS INDEX; BODY WEIGHT; CHOLESTEROL, HDL; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEUPROLIDE; MALE; METABOLIC SYNDROME X; PROSTATIC NEOPLASMS;

EID: 43049097147     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23511     Document Type: Editorial

References (17)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
2. Xavier Pi-Sunyer. The metabolic syndrome: how to approach differing definitions. Med Clin North Am. 2007;91:1025-1040.
3. Smith MR, Lee H, McGovern F, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer differences from the classic metabolic syndrome. Cancer. 2008;110:2188-2194.
4. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977-1984.
5. Carroll P. Early stage prostate cancer-do we have a problem with over-detection, overtreatment or both? J Urol. 2005;173:1061-1062.
6. Tannock IF. Eradication of a disease: how we cured symptomless prostate cancer. Lancet. 2002;359:1341-1342.
7. Pilepieh MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61:1285-1290.
8. Bolla M, Descotes IL, Artignan X, Fourneret P. Adjuvant treatment to radiation: combined hormone therapy and external radiotherapy for locally advanced prostate cancer. BJU Int. 2007;100(suppl 2):44-47.
9. Messing EM, Manola J, Yao I, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7:472-479.
10. Roach M 3rd, Bae K, Speight I, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;20:585-591.
11. Nair B, Wilt T, MacDonald R, et al. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev. 2002;(1):CD003506.
12. Moul IW, Wu II, Sun L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004;171:1141-1147.
13. Saigal CS, Gore JL, Krupski TL. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493-1500.
14. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448-1456.
15. Iligano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol. 2008;5:24-34.
16. Bylow K, Mohile SG, Stadler WM. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review. Cancer. 2007;110:2604-2613.
17. Ornish D, Weidner G, Fair WR, et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol. 2003;174:1065-1069.